Back to results
US 2012/0237930 A1Published application
Method of analyzing chromosomal translocations and a system therefore
AssigneeVentana Medical Systems, Inc.
InventorsHiro Nitta, Mike Farrell, Wenjun Zhang, Tom Grogan
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to systems and methods for analyzing chromosomal translocations, and in particular to analysis of chromosomal translocation by in situ hybridization.
Claims20
A method for analyzing a sample for a chromosomal translocation associated with a breakpoint comprising,
- contacting the sample with
- a first nucleic acid probe comprising a first sequence configured to hybridize to genomic DNA located 5′ to the breakpoint,
- a second nucleic acid probe comprising a second sequence configured to hybridize to genomic DNA located 3′ to the breakpoint, and
- a third nucleic acid probe comprising a third sequence configured to hybridize to genomic DNA adjacent to the breakpoint;
- establishing conditions suitable for the probes to hybridize to the genomic DNA in the sample;
- and
- detecting hybridization of the probes by detecting a first signal associated with the first nucleic acid probe, a second signal associated with the second nucleic acid probe, and a third signal associated with the third nucleic acid probe.
4 more elements
A kit for analyzing a sample for a chromosomal translocation associated with a breakpoint comprising:
- a first nucleic acid probe having a sequence configured to hybridize to a portion of the genomic DNA that is located 5′ to the breakpoint,
- a second nucleic acid probe having a sequence configured to hybridize to a portion of the genomic DNA that is located 3′ to the breakpoint, and
- a third nucleic acid probe having a sequence configured to hybridize to a portion of DNA that is adjacent to the breakpoint.
A method for diagnosing a disease associated with a chromosomal translocation associated with a breakpoint in a patient sample comprising:
- contacting the patient sample with a series of nucleic acid probes under conditions suitable for the probes to hybridize to the genomic DNA in the patient sample, the series selected so that in the absence of the chromosomal translocation associated with the breakpoint, the series hybridizes to the genomic DNA in the patient sample according to a first order and orientation, and so that in the presence of the chromosomal translocation associated with the breakpoint, the series hybridizes to the patient sample according a different order and orientation and
- detecting the order and orientation of the series of nucleic acid probes hybridized to the genomic DNA in the patient sample, wherein detecting the first order and orientation provides a diagnosis that the patient sample does not have the chromosomal translocation associated with the breakpoint in the patient sample.
Dependencies are inferred from the claim text.